The cluster is too small relative to market cap to warrant a bearish read-through. Freeman's sale coincides with a derivative exercise, indicating tax/vesting-related liquidity rather than informed selling. Monitor next earnings for fundamental trends, but this filing alone does not signal deterioration.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $128.81entry
- T+1 · 6mo ago −0.30%α −0.56% · $128.42
- T+5 · 6mo ago −3.04%α −0.52% · $124.89
- T+20 · 5mo ago +15.84%α +19.48% · $149.22
- T+60 · 3mo ago +26.68%α +25.75% · $163.18
Price Chart
How similar events traded
Executive Summary
A cluster of insider sales at Guardant Health totaling $5.01M over a 7-day window, led by the Chief Commercial Officer ($2.90M) and Chief Legal Officer ($1.25M), represents approximately 0.03% of the $16.9B market cap. While the dollar amount is trivial relative to company size, the cluster includes C-suite executives and coincides with derivative exercises by Freeman, suggesting liquidity-driven selling rather than a bearish signal.
Key Financial Metrics
Key Facts
- 5 insiders sold shares totaling $5.01M over May 20-27, 2026
- Chief Commercial Officer Chris Freeman sold $2.90M after exercising derivatives at $32.86/share
- Chief Legal Officer John Saia sold $1.25M at $125.08/share
- Total sales represent ~0.03% of Guardant Health's $16.9B market cap
- Freeman's derivative exercise (24,406 shares at $32.86) was a non-cash event paired with an open-market sale
- Analyst consensus is 88% bullish (29 Buy/Strong Buy, 4 Hold)
Financial Impact
Total insider sales of $5.01M, or 0.03% of market cap, immaterial relative to company size
Risk Factors
- If future insider sales accelerate in dollar volume or involve additional C-suite members without derivative exercises, the signal would strengthen
- The stock's strong run (up ~44% in 30 days per prior report) may have prompted routine portfolio rebalancing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-GH-1780007590777 |
Track record
38 reports on GH
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.49% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $145.04 Now $144.03 −0.70% settles Dec 16
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $150.87 Now $144.03 −4.53% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $153.43 Now $144.03 −6.13% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $168.58 Now $144.03 −14.56% settles Dec 3
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $175.00 Now $144.03 −17.70% settles Dec 2
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $162.94 Now $144.03 −11.61% settles Nov 19
- Oct 14, 20264w ago 144 Neutral 2/10 Entry $165.88 to $154.86 Now $144.03 −13.17% ▼ −6.64% −4.74% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 5/10 Entry $179.38 to $158.60 Now $144.03 +19.71% ▲ +11.58% +11.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers